NSAIDs ameliorate cognitive and motor impairment in a model of parkinsonism induced by chlorpromazine

Pakistan Journal of Pharmaceutical Sciences

Volumn 30, Issue 3, 2017, Pages 801-808

  Naeem, Sadaf ^a   Ikram, Rahila ^a   Khan, Saira Saeed ^a   Rao, Sadia Saleem ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

Anti inflammatory drugs (NSAIDs); Chlorpromazine (CPZ); Memory impairment; Neuroprotection; Parkinson's disease (PD)

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CELECOXIB; CHLORPROMAZINE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; GRIP STRENGTH; LONG TERM MEMORY; MALE; MOTOR COORDINATION; MOTOR DYSFUNCTION; MUSCLE STRENGTH; NONHUMAN; OPEN FIELD TEST; PARKINSONISM; PASSIVE AVOIDANCE TEST; RAT; SHORT TERM MEMORY; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED; COGNITION DISORDERS; DRUG EFFECTS; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CHLORPROMAZINE; COGNITION DISORDERS; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR;

EID: 85018933386     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Ambhore NS, Prasanna M, Antony AS, Kumar MNS (2014). Elango K. Pharmacological and anti oxidant evaluation of Aspirin, nimodipine and its combination for anti-Parkinson's activity in MPTP induced rat model, 3(1): 14-22.
2. Bais S, Gill NS and Kumar N (2015). Neuroprotective Effect of Juniperuscommunis on Chlorpromazine Induced Parkinson Disease in Animal Model: Chinese Journal of Biology, Volume 2015 (2015), Article ID 542542, 7 pages.
3. Bishnoi M, Chopra K and Kulkarni SK (2006). Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. European Journal of Pharmacology, 552(1-3): 55-66.
4. Choi D.K, Koppula S, Choi M and Suk K (2010). Recent developments in the inhibitors of neuroinflammation and neurodegeneration: Inflammatory oxidative enzymes as a drug target, Expert Opinion on Therapeutic Patents, 20(11): 1531-1546.
5. Choi S.H, Aid S and Bosetti F (2009). The distinct roles of cyclooxygenase-1 and-2 in neuroinflammation: implications for translational research. Trends Pharmacol. Sci., 30: 174-181
6. Choi S.H, Aid S and Caracciolo L et al (2013). Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. Journal of Neurochemistry, 124(1): 59-68.
7. Choi SH and Bosetti F (2009). Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging., 1: 234-244.
8. Combs CK, Johnson DE, Karlo JC, Cannady SB and Landreth GE (2000). Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloidstimulated proinflammatory responses and neurotoxicity by PPARagonists. J. Neurosci., 20: 558-567.
9. Deavall DG, Martin EA, Horner JM and Roberts R (2012). Drug-Induced Oxidative Stress and Toxicity; Journal of Toxicology: Volume 2012, Article ID 645460, 13 pages
10. De La Garza R and Asnis GM (2003). The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus. Brain Res., 977(1): 70-79.
11. Dexter DT, Holley AE and Flitter ET et al (1994). Increased levels of lipid hydroperoxides in the Parkinsoniansubstantianigra: An HPLC and ESR study, Movement Disorders, 9(1): 92-97.
12. Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC and Marchetti B (2010). Glia as a turning point in the therapeutic strategy in Parkinson's disease: CNS Neurol. Disord Drug Targets, 9: 349-372.
13. Fahn S and Przedborski S (2000). In Merritt's Neurology, ed Rowland LP (Lippincott, Williams & Wilkins, New York. pp.679-693.
14. Felicity N, Michael B, Olivia D and Ashley IB (2008). Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. Int. J. Neuropsychopharmacol., 11: 851-876
15. Glass CK, Saijo K, Winner B, Marchetto MC and Gage FH (2010). Mechanisms underlying inflammation in neurodegeneration. Cell, 140: 918-934.
16. Griffin WS (2006). Inflammation and neurodegenerative diseases: Am. J. Clin. Nutr., 83: 470-474.
17. Hoozemans JJ, Rozemuller JM, van Haastert ES, Veerhuis R and Eikelenboom P (2008). Cyclooxygenase-1 and-2 in the different stages of Alzheimer's disease pathology. Curr. Pharm. Des., 14: 1419.
18. Hoozemans JJ and O'Banion MK (2005). The role of COX-1 and COX-2 in Alzheimer's diseasepathology and the therapeutic potentials of non-steroidal antiinflammatory drugs. Curr. Drug Targets CNS. Neurol. Disord., 4: 307-315.
19. Imbimbo BP, Solfrizzi V and Panza F (2010). Are NSAIDs Useful to Treat Alzheimer's Disease or Mild Cognitive Impairment? Frontiers in Aging Neuroscience, 2: 19.
20. Johansson D, Falk A, Marcus MM and Svensson TH (2012). Celecoxib enhances the effect of reboxetine and fluxetine on cortical noradrenaline and serotonin output in the rat. Prog. Neuropsychopharmacol. Biol. Psychaitry, 39(1): 143-148.
21. Kaizaki A, Tien LT, Pang Y, Cai Z, Tanaka S, Numazawa S and Fan LW (2013). Celecoxib reduces brain dopaminergic neuronaldysfunction and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide. Journal of Neuroinflammation, 10: 45.
22. Kaizaki A, Tien LT and Pang Y et al (2013).Celecoxib reduces brain dopaminergic neuronaldysfunction and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide. Journal of Neuroinflammation, 10: 45.
23. Khaliq S, Haider S, Ahmed S.P, Perveen T and Haleem DJ (2006). Relationship of brain tryptophan and serotonin in improving cognitive performance in rats. Pak. J. Pharm. Sci., 19(1): 11-15.
24. Kim YS and Joh TH (2006). Microglia, major player in the brain inflammation: Their roles in the pathogenesis of Parkinson's disease, Experimental and Molecular Medicine, 38(4): 333-347.
25. Kotilinek LA, Westerman MA, Wang Q, Panizzon K, Lim GP, Simonyi A and Ashe KH (2008). Cyclooxygenase-2 inhibition improves amyloid-β-mediated suppression of memory and synaptic plasticity. Brain; a Journal of Neurology, 131(Pt 3): 651-664.
26. Li J, O, W, Li W, Jiang ZG and Ghanbari HA (2013). Oxidative Stress and Neurodegenerative Disorders. International Journal of Molecular Sciences, 14(12): 24438-24475.
27. Lima IV de A, Bastos LFS, Limborço-Filho M, Fiebich BL and de Oliveira ACP (2012). Role of Prostaglandins in Neuroinflammatory and Neurodegenerative Diseases: Mediators of Inflammation, 946813.
28. McAfoose J and Baune BT (2009). Evidence for a cytokine model of cognitive function. Neurosci. Biobehav. Rev., 33: 355-366.
29. McGeer PL, McGeer E and Yasojima K (2000). Alzheimer disease and neuroinflammation, in Advances in Dementia Research, 10: 53-57.
30. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, LaFerla FM, Jenkins BG, Kowall NW, Dedeoglu A (2008). Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res., 1207: 225-23610.
31. Menza M, DeFronzo Dobkin R and Marin H et al (2010). The Role of Inflammatory Cytokines in Cognition and other Non-Motor Symptoms of Parkinson's Disease. Psychosomatics, 51(6): 474-479.
32. Morris RGM (1981). Spatial localization does not require the presence of local cues, Learning and Motivation, 12(2): 239-260.
33. Mrak RE and Griffin WS (2005). Glia and their cytokines in progression of neurodegeneration: Neurobiol Aging; 26: 349-354.
34. Myhrer T (2003). Neurotransmitter systems involved in learning and memory in the rat: A meta-analysis based on studies of four behavioral tasks. Brain Res. Brain Res. Rev., 41(2-3): 268-287.
35. Naeem S, Najam R and Alam N (2015). Antidepressant effect of diclofenac against experimental parkinson's rat model. American Journal of Pharmacological Sciences, 3(3): 74-78.
36. Naidu PS, Singh A and Kulkarni SK (2002). Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms. British Journal of Pharmacology, 136(2): 193-200.
37. Parepally JM, Mandula H and Smith QR (2006). Brain uptake of nonsteroidal anti-inflammatory drugs: Ibuprofen, flurbiprofen and indomethacin. Pharm. Res., 23: 873-881.
38. Parikh V, Khan MM and Mahadik SP (2003). Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid per oxidation in rat brain, J. Psychiatr. Res., 37: 43-51.
39. Pepicelli O, E Fedele, M Berardi, M Raiteri, G Levi, A Greco, MA Ajmone-Cat and L Minghetti (2005). Cyclo oxygenase-1 and-2 differently contribute to prostaglandin E2 synthesis and lipid peroxidation after in vivo activation of N-methyl-D-aspartate receptors in rathippocampus. J. Neurochem., 93: 1561-1567.
40. Pires JG, Bonikovski V and Futuro-Neto HA (2005). Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. Braz. J. Med. Biol Res., 38(12):1867-72.
41. Ransohoff RM and Perry VH (2009). Microglial physiology: unique stimuli, specialized responses: Annual Review of Immunology, 27: 119-145.
42. Roberts J and Morrow J (2001). Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment gout. In: Hardman JG, Limbird LE, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th edn. New York: McGraw-Hill; 2001. pp.687-731.
43. Sandhu K and Rana A (2013). Evaluation of antiparkinson's activity of Nigella Sativa seeds in chlorpromazine induced experimental animal model. Academic Sciences, 5(Suppl 3): 0975-1491.
44. Savitt JM, Dawson VL and Dawson TM (2006) Diagnosis and treatment of Parkinson disease: Molecules to medicine. J. Clin. Invest, 116: 1744-1754.
45. Schlichtiger J, Pekcec A, Bartmann H, Winter P, Fuest C, Soerensen J and Potschka H (2010). Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy. British Journal of Pharmacology, 160(5): 1062-1071.
46. Sestakova N, Puzserova A, Kluknavsky M and Bernatova I (2013). Determination of motor activity and anxietyrelated behaviour in rodents: methodological aspects and role of nitric oxide. Interdisciplinary Toxicology, 6(3): 126-135.
47. Shin HW and Chung SJ (2012). Drug-induced parkinsonism. Journal of Clinical Neurology, 8(1): 15-21.
48. Shungu DC, Weiduschat N, Murrough JW, Mao X, Pillemer S and Dyke JP et al. (2012). Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology.
49. Small GW, Siddarth P, Silverman DHS, Ercoli LM, Miller KJ, Lavretsky H and Phelps ME (2008). Cognitive and Cerebral Metabolic Effects of Celecoxib Versus Placebo in People With Age-Related Memory Loss: Randomized Controlled Study. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry, 16(12): 999-1009.
50. Swiatkiewicz M, Zaremba M, Joniec I, Cztonkowski A and Kurkowska-Jastrzebska I (2013). Potential neuroprotective effect of ibuprofen, insight from the mice model of Parkinson disease: Pharmacological reports, 65: 1227-1236. Issue 1734-1140.
51. Takahashi E, Niimi K and Itakura C (2009). Motor coordination impairment in aged heterozygous rolling Nagoya, Cav2.1 mutant mice. Brain research; 1279: 50-57.
52. Tansey MG and Goldberg MS (2010). Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis., 37: 510-518.
53. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V and Przedborski S (2003). Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. USA, 100: 5473-5478.
54. Vafaee F, Hosseini M and Hassanzadeh Z et al (2015). The effects of Nigella sativa hydro-alcoholic extract on memory and brain tissues oxidative damage after repeated seizures in rats. Iranian Journal of Pharmaceutical Research, 14(2): 547-557.
55. Vasant-More S, Kumar H, Kim IS, Song SY and Choi DK (2013). Cellular and Molecular Mediators of Neuroinflammation in the Pathogenesis of Parkinson's Disease. Mediators of Inflammation. Article ID 952375, 12 pages.
56. Vorhees CV and Williams MT (2006). Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nature Protocols, 1(2): 848-858.
57. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P (2011). Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by anti-inflammatory drugs in mice and humans. Proc. Natl. Acad. Sci. USA. 108: 9262-9267.
58. Whitton PS (2007). Inflammation as a causative factor in the aetiology of Parkinson's disease. British Journal of Pharmacology, 150(8): 963-976.
59. Wise RA and Bozarth MA (1987). A psychomotor stimulant theory of addiction. Psychol. Rev., 94: 469-492.
60. Yermakova AV, Rollins J, Callahan LM, Rogers J and O'Banion MK (1999). Cyclooxygenase-1 in human Alzheimer and control brain: Quantitative analysis of expression by microglia and CA3 hippocampal neurons. J. Neuropathol. Exp. Neurol., 58: 1135-1146.
61. YinxiaC, Siew CW and Eng King T (2014). Evidence of Inflammatory System Involvement in Parkinson's Disease: BioMed Research International Volume 2014, Article ID 308654, 9 pages.
62. Zhang WT and Wang Z Pei et al (2005). Aggregated α-synuclein activates microglia: A process leading to disease progression in Parkinson's disease: The FASEB Journal, 19(6): 533-542.